AI in drug discovery: A wake-up call.

Journal: Drug discovery today
Published Date:

Abstract

Following a proof-of-concept presentation on dual-use artificial intelligence (AI) in drug discovery by Collaborations Pharmaceuticals Inc. to the Swiss Federal Institute for NBC-Protection, we explored how a generative algorithm could develop the nerve agent VX and tens of thousands of analogs in a highly impactful commentary. We not only laid out the experiment, but, with guidance from experts on arms control and dual-use, we called for more discussion around the general repurposing potential of AI in drug discovery. To continue that conversation, we now share further details on the experiment and place our experiences in the larger frame of other scientists who have similarly developed powerful technologies but without engaging with, or even truly understanding, the misuse potential and downstream consequences of the technologies. It is our sincere hope that our experiment may serve as an important wake-up call for users of generative AI.

Authors

  • Fabio Urbina
    Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, 27606, USA.
  • Filippa Lentzos
    Department of War Studies and Department of Global Health & Social Medicine, King's College London, United Kingdom.
  • Cédric Invernizzi
    Spiez Laboratory, Federal Department of Defence, Civil Protection and Sports, Switzerland.
  • Sean Ekins
    Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA; Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA; Collaborations Pharmaceuticals, Inc., 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA; Phoenix Nest, Inc., P.O. Box 150057, Brooklyn, NY 11215, USA; Hereditary Neuropathy Foundation, 401 Park Avenue South, 10th Floor, New York, NY 10016, USA. Electronic address: ekinssean@yahoo.com.